Launch week offerEnds in00h00m00s

annual Promonthly Pro

Dan Cacsire Castillo-Tong

Group leader / Prof. Dr

Medical University of Vienna

Austria

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Austria Professors in Biostatistics Biostatistics professors in Austria

Articles (13)

Year:

2026

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (12)

Rudolf Karch

Associate Professor

Medical University of Vienna

AUSTRIA

View details

Ewa Marcinkowska

professor

University of Wrocław

POLAND

View details

Christian F. Singer

Medical University of Vienna

AUSTRIA

View details

Martin Schepelmann

Group Leader / PI

Medical University of Vienna

AUSTRIA

View details

Leonhard Müllauer

Pathologist/Molecular Pathologist/Associate Professor

Medical University of Vienna

AUSTRIA

View details

Christoph Grimm

Medical University of Vienna

AUSTRIA

View details

Enikö Kallay

Assoc. Prof

Medical University of Vienna

AUSTRIA

View details

Wolfgang Schreiner

Medical University of Vienna

AUSTRIA

View details

Karina Piatek

Medical University of Vienna

AUSTRIA

View details

Michał Chodyński

chief specialist

POLAND

View details

Markus Morkel

Research Group Leader

Charité - Universitätsmedizin Berlin

GERMANY

View details

Thomas Bartl

Medical Specialist

Medical University of Vienna

AUSTRIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Dan Cacsire Castillo-Tong

Research Interests

Make your next move.

Explore related searches

Articles (13)

Targeting RAS–RAF–MEK–ERK signaling in mucinous ovarian cancer: a translational evidence synthesis and clinical framework

Therapeutic Effects of Lurbinectedin in PARP Inhibitor-Resistant High-Grade Serous Ovarian Cancer Using Patient-Derived Cell Lines and Organoid Models

AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication

Biomarkers for checkpoint inhibitor therapy in mucinous epithelial ovarian cancer

SLCO4A1 expression is associated with activated inflammatory pathways in high-grade serous ovarian cancer

Decision Theory versus Conventional Statistics for Personalized Therapy of Breast Cancer

Vitamin D Analogs Regulate the Vitamin D System and Cell Viability in Ovarian Cancer Cells

Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients

Decision theory for precision therapy of breast cancer

Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer

Microarray Normalization Revisited for Reproducible Breast Cancer Biomarkers

Pretreatment with methanolic extract of Pistacia lentiscus L. increases sensitivity to DNA damaging drugs in primary high-grade serous ovarian cancer cells

Collaborators (12)

Rudolf Karch

Ewa Marcinkowska

Christian F. Singer

Martin Schepelmann

Leonhard Müllauer

Christoph Grimm

Enikö Kallay

Wolfgang Schreiner

Karina Piatek

Michał Chodyński

Markus Morkel

Thomas Bartl

Make your next move.